Catalog Products » SARS-CoV-2 Spike protein (RBD, E484K, K417T, N501Y, Avi & His Tag)-HRP
Manual
Manual
COAs

SARS-CoV-2 Spike protein (RBD, E484K, K417T, N501Y, Avi & His Tag)-HRP

*This product has been discontinued!*
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. Lineage P.1, also known as the Brazil(ian) variant is one of the variants of SARS-CoV-2. This variant has 17 amino acid changes, ten of which are in its spike protein, including these three designated to be of particular concern: N501Y, E484K and K417T.
Z03601
Ask us a question
Product Introduction
Species SARS-CoV-2
Protein Construction

Expressed with the mutations of E484K, K417T, N501Y.

Spike RBD (Arg319-Ser591)
Accession # P0DTC2		 Avi Poly-His
N-term C-term
Conjugate HRP
Biological Activity This protein is validated to bind with human ACE2 (Cat. No. Z03516) in functional ELISA assay.
Expression System CHO
Application The optimal dilution ratio should be determined by the end user for specific applications.
ELISA 1:1000
Formulation Supplied as a solution in PBS, pH 7.4, 0.1% ProClin 300.
Storage & Stability Upon receiving, this product remains stable for up to 3 months at 2-8°C. Protect from light.
Back

Background
Target Background SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. Lineage P.1, also known as the Brazil(ian) variant is one of the variants of SARS-CoV-2. This variant has 17 amino acid changes, ten of which are in its spike protein, including these three designated to be of particular concern: N501Y, E484K and K417T.
Synonyms Lineage P.1; 20J/501Y.V3; VOC-202101/02; Brazil(ian) variant; Gamma variant
References 1. Variants: distribution of cases data. GOV.UK. Retrieved 27 February 2021. 
2. COVID-19: Virologist says Brazilian coronavirus variant detected in UK is not the one 'of concern'. 
3. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. 
Back

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.